Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “hold” rating reaffirmed by stock analysts at Credit Suisse Group in a note issued to investors on Monday. They currently have a $81.00 price target on the biotechnology company’s stock. Credit Suisse Group’s target price would suggest a potential upside of 0.12% from the stock’s previous close.
Other research analysts have also issued research reports about the stock. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 10th. Zacks Investment Research lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. UBS Group reaffirmed an “outperform” rating and set a $56.51 price objective (down previously from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. HC Wainwright set a $75.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Monday, February 12th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $76.12 price objective (down previously from $83.00) on shares of Sarepta Therapeutics in a research report on Monday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have assigned a buy rating to the stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $72.17.
Sarepta Therapeutics (SRPT) opened at $80.90 on Monday. The company has a market cap of $5,230.00, a PE ratio of -101.13 and a beta of 1.51. The company has a current ratio of 13.91, a quick ratio of 12.96 and a debt-to-equity ratio of 0.54. Sarepta Therapeutics has a 52-week low of $28.14 and a 52-week high of $83.30.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. 361 Capital LLC bought a new stake in Sarepta Therapeutics in the third quarter valued at about $1,914,000. Janney Montgomery Scott LLC bought a new stake in Sarepta Therapeutics in the third quarter valued at about $474,000. Jennison Associates LLC increased its stake in Sarepta Therapeutics by 0.6% in the fourth quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock valued at $63,998,000 after acquiring an additional 6,357 shares during the period. Hikari Power Ltd bought a new stake in Sarepta Therapeutics in the third quarter valued at about $1,134,000. Finally, Oppenheimer & Co. Inc. increased its stake in Sarepta Therapeutics by 53.0% in the third quarter. Oppenheimer & Co. Inc. now owns 33,592 shares of the biotechnology company’s stock valued at $1,524,000 after acquiring an additional 11,639 shares during the period. 85.14% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3260528/credit-suisse-group-reiterates-hold-rating-for-sarepta-therapeutics-srpt.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.